VAXX
PINK Vaxxinity Inc Class A$0.0001 ↑ +0.0000 (+0.00%) Trading Up from the previous close of $0.0001, and at the day’s high of $0.0001
- YTD change
- -66.67%
- vs 20-day SMA
- -98.13%
- vs 200-day SMA
- -97.27%
Price ranges
Price & Performance
+0.00 (+0.00%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 100.0% away from all-time highs of $22.7700
- VAXX is down 67% since the beginning of the year
- VAXX is down 100% over the past 12 months
- VAXX is up 0% over the past 1 month
- 0% of all VAXX investors are betting against VAXX
VAXX reads n/a: price sits below both the 20- and 200-day averages, the 12-month move is +0.0%.
- Previous minute
- +$0.0000
- Last hour
- +$0.0000
- Last 5 days
- +0.00%
- vs 8-day SMA
- +0.00%
No alerts for VAXX in the last day.
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Vaxxinity, Inc. is a biotechnology company that aims to democratize health by bringing the efficiency of vaccines to chronic diseases. The company uses its synthetic peptide vaccine platform to harness the immune system and convert the body into its own 'drug factory', stimulating the production of antibodies with a therapeutic effect. Its current pipeline consists of five chronic disease candidates from early to late-stage development across multiple therapeutic areas including Alzheimer’s, Parkinson’s, migraine and hypercholesterolemia as well as a candidate for COVID-19 prevention. The company was founded by Louis G. Reese IV and Mei Mei Hu in 2014 and is headquartered in Exploration Park, FL.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
